Lab Phone:
646-888-2796
Education:
University of Michigan Ann Arbor
Mentor:
Ross L. Levine

Publications by Lindsay M. Saunders

Dawson, M., Bannister, A., Saunders, L., Wahab, O., Liu, F., Nimer, S., Levine, R., Göttgens, B., Kouzarides, T., Green, A. (2011) Nuclear JAK2. Blood, 118, 6987-6988. PMID: 22194397.

Dey, A., Seshasayee, D., Noubade, R., French, D., Liu, J., Chaurushiya, M., Kirkpatrick, D., Pham, V., Lill, J., Bakalarski, C., Wu, J., Phu, L., Katavolos, P., LaFave, L., Abdel-Wahab, O., Modrusan, Z., Seshagiri, S., Dong, K., Lin, Z., Balazs, M., Suriben, R., Newton, K., Hymowitz, S., Garcia-Manero, G., Martin, F., Levine, R., Dixit, V. (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. Science, 337, 1541-1546. PMID: 22878500.

Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L., Mullally, A., Abdel-Wahab, O., Leung, L., Weinstein, A., Marubayashi, S., Goel, A., Gönen, M., Estrov, Z., Ebert, B., Chiosis, G., Nimer, S., Berstein, B., Verstovsek, S., Levine, R. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 489, 155-159. PMID: 22820254; PMCID: PMC3991463.

Abdel-Wahab, O., Adli, M., LaFave, L., Gao, J., Hricik, T., Shih, A., Pandey, S., Patel, J., Chung, Y., Koche, R., Perna, F., Zhao, X., Taylor, J., Park, C., Carroll, M., Melnick, A., Nimer, S., Jaffe, J., Aifantis, I., Bernstein, B., Levine, R. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell, 22, 180-193. PMID: 22897849; PMCID: PMC3422511.

LaFave, L., Levine, R. (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci, 33, 574-582. PMID: 22995223.

LaFave, L., Levine, R. (2013) Mining the epigenetic landscape in ALL. Nat Genet, 45, 1269-1270. PMID: 24165727.

Abdel-Wahab, O., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y., Kuscu, C., Hricik, T., Ndiaye-Lobry, D., LaFave, L., Koche, R., Shih, A., Guryanova, O., Kim, E., Li, S., Pandey, S., Shin, J., Telis, L., Liu, J., Bhatt, P., Monette, S., Zhao, X., Mason, C., Park, C., Bernstein, B., Aifantis, I., Levine, R. (2013) Deletion of Asxl1 results in myelodysplasia and sever developmental defects in vivo. J Exp Med, 210, 2641-2659. PMID: 24218140; PMCID: PMC3832937.